GBR-1302

N/A

Report date: 2026/03/19 16:46:20

Base Information

Drug NameGBR-1302

Drug Alias NameAnti-HER2-anti-CD3-antibodyHBM-9302GBR-1302

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-HER2

TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlenmark Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIchnos Sciences Sa Harbour Biomed Glenmark Pharmaceuticals Sa

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A